LPA-话题@MedSci

#LPA#

22篇内容 | 1907人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2182859, encodeId=eee82182859d5, content=<a href='/topic/show?id=f5ce5131ec9' target=_blank style='color:#2F92EE;'>#心肌缺血#</a> <a href='/topic/show?id=9b0d850264e' target=_blank style='color:#2F92EE;'>#脑脊液#</a> <a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Basic Res Cardiol 安徽医科大学第二附属医院何淑芳/张野团队揭示脊髓LPA/TRPV1信号调控心肌缺血损伤, objectType=article, longId=810234, objectId=248981023472, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=248981023472, replyNumber=0, likeNumber=164, createdTime=2024-01-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=248981023472, moduleTitle=Basic Res Cardiol 安徽医科大学第二附属医院何淑芳/张野团队揭示脊髓LPA/TRPV1信号调控心肌缺血损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=248981023472)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1581421, encodeId=ec51158142117, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=JACC：新晋“坏”血脂LPa升高居然会增加心房颤动的风险, objectType=article, longId=724815, objectId=35aee24815fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35aee24815fe, replyNumber=0, likeNumber=99, createdTime=2022-04-24, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35aee24815fe, moduleTitle=JACC：新晋“坏”血脂LPa升高居然会增加心房颤动的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35aee24815fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581420, encodeId=bc8c1581420c1, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=JACC：LPA KIV-2突变降低了脂蛋白（a）的浓度并降低冠状动脉疾病的发生, objectType=article, longId=215129, objectId=954a2151293d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954a2151293d, replyNumber=0, likeNumber=94, createdTime=2021-08-02, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954a2151293d, moduleTitle=JACC：LPA KIV-2突变降低了脂蛋白（a）的浓度并降低冠状动脉疾病的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954a2151293d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581419, encodeId=4da515814195b, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=BMC Gastroenterology：血清溶血磷脂酶自分泌蛋白(ATX)和溶血磷脂酸(LPA)可以作为胰腺癌潜在诊断生物标志物, objectType=article, longId=207207, objectId=b2ff20e20786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ff20e20786, replyNumber=0, likeNumber=56, createdTime=2021-02-18, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ff20e20786, moduleTitle=BMC Gastroenterology：血清溶血磷脂酶自分泌蛋白(ATX)和溶血磷脂酸(LPA)可以作为胰腺癌潜在诊断生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ff20e20786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581418, encodeId=44da15814185c, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle= Clinica Chimica Acta：疑似家族性高胆固醇血症患者的冠状动脉疾病和风险相关LPA变异？, objectType=article, longId=199103, objectId=0c52199103bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c52199103bd, replyNumber=0, likeNumber=79, createdTime=2020-08-11, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c52199103bd, moduleTitle= Clinica Chimica Acta：疑似家族性高胆固醇血症患者的冠状动脉疾病和风险相关LPA变异？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c52199103bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581417, encodeId=25b2158141e16, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Clinica Chimica Acta：导致LPAC综合征的纯合子ABCB4突变演变为胆管癌, objectType=article, longId=181506, objectId=2993181506a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2993181506a3, replyNumber=0, likeNumber=74, createdTime=2019-10-19, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2993181506a3, moduleTitle=Clinica Chimica Acta：导致LPAC综合征的纯合子ABCB4突变演变为胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2993181506a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581416, encodeId=b4fe158141686, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=由于细菌污染，辉瑞公司紧急召回偏头痛药物Relpax, objectType=article, longId=177797, objectId=88981e7797a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88981e7797a2, replyNumber=0, likeNumber=80, createdTime=2019-08-18, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88981e7797a2, moduleTitle=由于细菌污染，辉瑞公司紧急召回偏头痛药物Relpax, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88981e7797a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581415, encodeId=5597158141597, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据, objectType=article, longId=164229, objectId=06b01642297b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06b01642297b, replyNumber=0, likeNumber=0, createdTime=2019-04-15, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06b01642297b, moduleTitle=2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06b01642297b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581414, encodeId=603d1581414eb, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Blood：HAP1基因缺失可通过下调calpain-1-Bid-caspase-3/12信号通路使ALL患者对左旋 -天冬酰胺酶产生耐药性, objectType=article, longId=163559, objectId=ae02163559ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae02163559ca, replyNumber=0, likeNumber=87, createdTime=2019-04-05, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae02163559ca, moduleTitle=Blood：HAP1基因缺失可通过下调calpain-1-Bid-caspase-3/12信号通路使ALL患者对左旋 -天冬酰胺酶产生耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae02163559ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581413, encodeId=01001581413dc, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析, objectType=article, longId=157446, objectId=175b15e44699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=175b15e44699, replyNumber=0, likeNumber=62, createdTime=2019-01-08, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=175b15e44699, moduleTitle=J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=175b15e44699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581412, encodeId=04c915814126c, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全, objectType=article, longId=149345, objectId=898214934537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898214934537, replyNumber=0, likeNumber=73, createdTime=2018-09-23, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898214934537, moduleTitle=J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898214934537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581411, encodeId=53c81581411a4, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=J Hepatol：采用Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植受者, objectType=article, longId=147738, objectId=506414e73818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=506414e73818, replyNumber=0, likeNumber=67, createdTime=2018-08-31, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=506414e73818, moduleTitle=J Hepatol：采用Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植受者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=506414e73818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581410, encodeId=b653158141023, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=JAMA：PCI围术期患者需要应用负荷剂量他汀吗？从ARMYDA-ACS到ALPACS与ISCAP,再到SECURE-PCI, objectType=article, longId=132152, objectId=afd513215299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afd513215299, replyNumber=0, likeNumber=51, createdTime=2018-03-13, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afd513215299, moduleTitle=JAMA：PCI围术期患者需要应用负荷剂量他汀吗？从ARMYDA-ACS到ALPACS与ISCAP,再到SECURE-PCI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afd513215299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581409, encodeId=e532158140903, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Lancet Gastroent Hepatol：Seladelpar，PPAR-δ选择性激动剂，对原发性胆管炎的治疗效果和安全性。, objectType=article, longId=108955, objectId=ab22108955ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab22108955ed, replyNumber=0, likeNumber=75, createdTime=2017-08-18, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab22108955ed, moduleTitle=Lancet Gastroent Hepatol：Seladelpar，PPAR-δ选择性激动剂，对原发性胆管炎的治疗效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab22108955ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581408, encodeId=3f5215814083a, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估, objectType=article, longId=100420, objectId=5e0f100420cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e0f100420cd, replyNumber=0, likeNumber=64, createdTime=2017-06-03, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e0f100420cd, moduleTitle=Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e0f100420cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581407, encodeId=af42158140eca, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=Eur Heart J：一种新的频繁LPA基因KIV-2变异与LP（a）和心血管疾病的风险降低相关！, objectType=article, longId=97233, objectId=ec1d9e2339a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec1d9e2339a, replyNumber=0, likeNumber=57, createdTime=2017-04-28, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec1d9e2339a, moduleTitle=Eur Heart J：一种新的频繁LPA基因KIV-2变异与LP（a）和心血管疾病的风险降低相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec1d9e2339a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581406, encodeId=b99c158140685, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=NEJM：Sofosbuvir 及Velpatasvir治疗基因型1、2、4、5及 6的HCV感染患者的效果, objectType=article, longId=61524, objectId=6a3c6152469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a3c6152469, replyNumber=0, likeNumber=89, createdTime=2016-01-04, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a3c6152469, moduleTitle=NEJM：Sofosbuvir 及Velpatasvir治疗基因型1、2、4、5及 6的HCV感染患者的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a3c6152469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581405, encodeId=052115814053f, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=NEJM：丙肝药物Sofosbuvir和Velpatasvir联用大获成功，肝硬化依然有效（ASTRAL系列研究）, objectType=article, longId=60052, objectId=a2a260052e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2a260052e3, replyNumber=0, likeNumber=56, createdTime=2015-12-04, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2a260052e3, moduleTitle=NEJM：丙肝药物Sofosbuvir和Velpatasvir联用大获成功，肝硬化依然有效（ASTRAL系列研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2a260052e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581404, encodeId=fd141581404c1, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案, objectType=article, longId=59145, objectId=256459145ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=256459145ee, replyNumber=0, likeNumber=84, createdTime=2015-11-21, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=256459145ee, moduleTitle=NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=256459145ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581403, encodeId=336015814031b, content=<a href='/topic/show?id=c0c9110333d' target=_blank style='color:#2F92EE;'>#LPA#</a>, objectTitle=NEJM：吉利德新药velpatasvir临床三期结果出炉, objectType=article, longId=58936, objectId=825f58936f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825f58936f5, replyNumber=0, likeNumber=86, createdTime=2015-11-19, rootId=0, userName=ms9474365431325850, userId=9a7b16794085, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825f58936f5, moduleTitle=NEJM：吉利德新药velpatasvir临床三期结果出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825f58936f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LPA

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#心肌缺血# #脑脊液# #LPA#

Basic Res Cardiol 安徽医科大学第二附属医院何淑芳/张野团队揭示脊髓LPA/TRPV1信号调控心肌缺血损伤

2024-01-20发表于陕西省

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

JACC：新晋“坏”血脂LPa升高居然会增加心房颤动的风险

2022-04-24

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

JACC：LPA KIV-2突变降低了脂蛋白（a）的浓度并降低冠状动脉疾病的发生

2021-08-02

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

BMC Gastroenterology：血清溶血磷脂酶自分泌蛋白(ATX)和溶血磷脂酸(LPA)可以作为胰腺癌潜在诊断生物标志物

2021-02-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Clinica Chimica Acta：疑似家族性高胆固醇血症患者的冠状动脉疾病和风险相关LPA变异？

2020-08-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Clinica Chimica Acta：导致LPAC综合征的纯合子ABCB4突变演变为胆管癌

2019-10-19

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

由于细菌污染，辉瑞公司紧急召回偏头痛药物Relpax

2019-08-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

2019年欧洲肝脏研究协会大会：PPARδ激动剂Seladelpar治疗原发性胆汁性胆管炎患者的II期阳性数据

2019-04-15

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Blood：HAP1基因缺失可通过下调calpain-1-Bid-caspase-3/12信号通路使ALL患者对左旋 -天冬酰胺酶产生耐药性

2019-04-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析

2019-01-08

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

J Hepatol：Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植患者，疗效显著且安全

2018-09-23

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

J Hepatol：采用Sofosbuvir/velpatasvir治疗HCV基因1-4型肝移植受者

2018-08-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

JAMA：PCI围术期患者需要应用负荷剂量他汀吗？从ARMYDA-ACS到ALPACS与ISCAP,再到SECURE-PCI

2018-03-13

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Lancet Gastroent Hepatol：Seladelpar，PPAR-δ选择性激动剂，对原发性胆管炎的治疗效果和安全性。

2017-08-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Hepatology：DAA治疗失败的基因1 型丙型肝炎患者中，Sofosbuvir-velpatasvir-voxilaprevir使用效果评估

2017-06-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

Eur Heart J：一种新的频繁LPA基因KIV-2变异与LP（a）和心血管疾病的风险降低相关！

2017-04-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

NEJM：Sofosbuvir 及Velpatasvir治疗基因型1、2、4、5及 6的HCV感染患者的效果

2016-01-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

NEJM：丙肝药物Sofosbuvir和Velpatasvir联用大获成功，肝硬化依然有效（ASTRAL系列研究）

2015-12-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案

2015-11-21

ms9474365431325850 (审核中...)

前往app查看评论内容

#LPA#

NEJM：吉利德新药velpatasvir临床三期结果出炉

2015-11-19

科室
- - 订阅+
  - 更多科室
工具
服务